Current Challenges for IDO2 as Target in Cancer Immunotherapy.
Mondanelli G, Mandarano M, Belladonna ML, Suvieri C, Pelliccia C, Bellezza G, Sidoni A, Carvalho A, Grohmann U, Volpi C.
Mondanelli G, et al. Among authors: sidoni a.
Front Immunol. 2021 Apr 21;12:679953. doi: 10.3389/fimmu.2021.679953. eCollection 2021.
Front Immunol. 2021.
PMID: 33968089
Free PMC article.
Review.